1. Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.
- Author
-
Boll LM, Vázquez Montes de Oca S, Camarena ME, Castelo R, Bellmunt J, Perera-Bel J, and Albà MM
- Subjects
- Humans, Programmed Cell Death 1 Receptor antagonists & inhibitors, Cohort Studies, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen metabolism, B7-H1 Antigen immunology, B7-H1 Antigen genetics, Treatment Outcome, Gene Expression Regulation, Neoplastic, Urinary Bladder Neoplasms immunology, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms therapy, Urinary Bladder Neoplasms pathology, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy methods, Mutation
- Abstract
Advanced bladder cancer patients show very variable responses to immune checkpoint inhibitors (ICIs) and effective strategies to predict response are still lacking. Here we integrate mutation and gene expression data from 707 advanced bladder cancer patients treated with anti-PD-1/anti-PD-L1 to build highly accurate predictive models. We find that, in addition to tumor mutational burden (TMB), enrichment in the APOBEC mutational signature, and the abundance of pro-inflammatory macrophages, are major factors associated with the response. Paradoxically, patients with high immune infiltration do not show an overall better response. We show that this can be explained by the activation of immune suppressive mechanisms in a large portion of these patients. In the case of non-immune-infiltrated cancer subtypes, we uncover specific variables likely to be involved in the response. Our findings provide information for advancing precision medicine in patients with advanced bladder cancer treated with immunotherapy., Competing Interests: Competing interests: Potential conflicts of interest: J.B. has served in consulting or advisory roles for Astellas Pharma, AstraZeneca/MedImmune, Bristol Myers Squibb, Genentech, Novartis, Pfizer, Pierre Fabre, and the healthcare business of Merck KGaA, Darmstadt, Germany; has received travel and accommodation expenses from Ipsen, Merck & Co., Kenilworth, NJ, and Pfizer; reports patents, royalties, other intellectual property from UpToDate; reports stock and other ownership interests in Rainier Therapeutics; has received honoraria from UpToDate; and has received institutional research funding from Millennium, Pfizer, Sanofi, and the healthcare business of Merck KGaA, Darmstadt, Germany. The remaining authors declare no competing interests., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF